<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Yonsei Med J</journal-id>
      <journal-id journal-id-type="iso-abbrev">Yonsei Med. J</journal-id>
      <journal-id journal-id-type="publisher-id">YMJ</journal-id>
      <journal-title-group>
        <journal-title>Yonsei Medical Journal</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0513-5796</issn>
      <issn pub-type="epub">1976-2437</issn>
      <publisher>
        <publisher-name>Yonsei University College of Medicine</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24142665</article-id>
      <article-id pub-id-type="pmc">3809851</article-id>
      <article-id pub-id-type="doi">10.3349/ymj.2013.54.6.1545</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
          <subj-group>
            <subject>Gastroenterology &amp; Hepatology</subject>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Successful Azathioprine Treatment with Metabolite Monitoring in a Pediatric Inflammatory Bowel Disease Patient Homozygous for <italic>TPMT<sup>*</sup>3C</italic></article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>Mi-Na</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Woo</surname>
            <given-names>Hye In</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>Yoo Min</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kang</surname>
            <given-names>Ben</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>Jong-Won</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Choe</surname>
            <given-names>Yon Ho</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Lee</surname>
            <given-names>Soo-Youn</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</aff>
      <aff id="A2"><label>2</label>Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</aff>
      <author-notes>
        <corresp>
Corresponding authors: Dr. Soo-Youn Lee, Department of Laboratory Medicine and Genetics, Department of Clinical Pharmacology and Therapeutics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea. Tel: 82-2-3410-1834, Fax: 82-2-3410-2719, <email>suddenbz@skku.edu</email></corresp>
        <corresp>
Corresponding authors: Dr. Yon Ho Choe, Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea. Tel: 82-2-3410-3527, Fax: 82-2-3410-0043, <email>yonho.choe@samsung.com</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <day>01</day>
        <month>11</month>
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>01</day>
        <month>10</month>
        <year>2013</year>
      </pub-date>
      <volume>54</volume>
      <issue>6</issue>
      <fpage>1545</fpage>
      <lpage>1549</lpage>
      <history>
        <date date-type="received">
          <day>11</day>
          <month>7</month>
          <year>2013</year>
        </date>
        <date date-type="rev-recd">
          <day>06</day>
          <month>8</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>13</day>
          <month>8</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Copyright: Yonsei University College of Medicine 2013</copyright-statement>
        <copyright-year>2013</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Thiopurine <italic>S</italic>-methyltransferase (TPMT) methylates purine analogues, showing TPMT activity in inverse relation to concentrations of active metabolites such as 6-thioguanine nucleotide (6-TGN). With conventional dosing of thiopurines, patients with homozygous variant <italic>TPMT</italic> alleles consistently suffer from severe myelosuppression. Here, we report a patient with <italic>TPMT<sup>*</sup>3C/<sup>*</sup>3C</italic> who managed successfully with monitoring of thiopurine metabolites. The patient was an 18-year-old male diagnosed with Crohn's disease. The standard dose of azathioprine (AZA) (1.8 mg/kg/day) with mesalazine (55.6 mg/kg/day) was prescribed. Two weeks after starting AZA treatment, the patient developed leukopenia. The DNA sequence analysis of <italic>TPMT</italic> identified a homozygous missense variation (NM_000367.2: c.719A&gt;G; p.Tyr240Cys), <italic>TPMT<sup>*</sup>3C/<sup>*</sup>3C</italic>. He was treated with adjusted doses of azathioprine (0.1-0.2 mg/kg/day) and his metabolites were closely monitored. Leukopenia did not reoccur during the follow-up period of 24 months. To our knowledge, this is the first case of a patient homozygous for <italic>TPMT<sup>*</sup>3C</italic> successfully treated with azathioprine in Korea. While a <italic>TPMT</italic> genotyping test may be helpful to determine a safe starting dose, it may not completely prevent myelosuppression. Monitoring metabolites as well as routine laboratory tests can contribute to assessing drug metabolism and optimizing drug dosing with minimized drug-induced toxicity.</p>
      </abstract>
      <kwd-group>
        <kwd>Thiopurine methyltransferase</kwd>
        <kwd>azathioprine</kwd>
        <kwd>inflammatory bowel disease</kwd>
        <kwd>metabolite levels</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source country="KR">Samsung Biomedical Research Institute</funding-source>
          <award-id>SBRI GL1-B2-211-1</award-id>
        </award-group>
      </funding-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>INTRODUCTION</title>
      <p>Azathioprine (AZA) plays a pivotal role in the treatment of inflammatory bowel disease (IBD). AZA rapidly changes to 6-mercaptopurine (6-MP) and consequently turns into 6-thioguanine nucleotides (6-TGN) by hypoxanthine-guanine phosphoribosyltransferase to exercise its immunosuppressive action. Alternatively, AZA is converted to inactive metabolites, 6-methylmercaptopurine (6-MMPN), by thiopurine <italic>S</italic>-methyltransferase (TPMT).</p>
      <p>To date, about 30 allelic variants of <italic>TPMT</italic> with affecting protein stability or enzymatic activity have been identified.<xref ref-type="bibr" rid="B1">1</xref> In Whites and Asians, <italic>TPMT<sup>*</sup>3A</italic> and <italic>TPMT<sup>*</sup>3C</italic> are the most important variants with low enzyme activity, respectively.<xref ref-type="bibr" rid="B2">2</xref>
<italic>TPMT<sup>*</sup>3A</italic> exhibits deficient activity, while <italic>TPMT<sup>*</sup>3C</italic> has moderate activity <italic>in vitro</italic>.<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref> In patients with deficient TPMT, 6-TGN is rapidly accumulated, causing potentially fatal myelotoxicity.<xref ref-type="bibr" rid="B2">2</xref></p>
      <p>Adverse effects, including myelosuppression, are found in 9-34% of IBD patients.<xref ref-type="bibr" rid="B5">5</xref> Consequently, AZA should be decreased or stopped in up to 30% of patients.<xref ref-type="bibr" rid="B6">6</xref> Considering the chronic course of IBD, it is important to optimize AZA dosing before treatment failure.<xref ref-type="bibr" rid="B6">6</xref> In cases with deficient TPMT, laboratory tests are applicable to measure thiopurine metabolites. These tests can confirm a TPMT phenotype and optimize personalized dosing to prevent myelosuppression.<xref ref-type="bibr" rid="B7">7</xref> Here, we report the first case of a Korean IBD patient homozygous for <italic>TPMT<sup>*</sup>3C</italic>, successfully treated with AZA by monitoring metabolite levels.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>An 18 year-old male was referred to our hospital for abdominal pain and loose stool. On physical examination, he had tenderness on the lower left quadrant of the abdomen. Routine laboratory tests, including complete blood cell counts (CBC) and liver function were all within normal limits except mild anemia and an elevated erythrocyte sediment rate of 82 mm/hr (reference interval, 0-22 mm/hr).</p>
      <p>The patient was diagnosed with Crohn's disease according to standard clinical, endoscopic, and histologic criteria. Oral treatment with AZA (1.8 mg/kg/day) and mesalazine (55.6 mg/kg/day) was started. Two weeks later, the absolute neutrophil count (ANC) and white blood cell count (WBC) decreased from 5140/&#xB5;L to 1010/&#xB5;L, and 6270/&#xB5;L to 2810/&#xB5;L, respectively. The AZA dosage was reduced from 1.8 to 0.9 mg/kg/day. Three weeks later, ANC and WBC continued to decline further to 190/&#xB5;L and 1910/&#xB5;L, respectively. The AZA was discontinued. After leukopenia was recovered, the patient was restarted on AZA (0.8 mg/kg/day) with the discontinuation of mesalazine. The patient's daily dose of AZA was cautiously increased to 1.2 mg/kg while monitoring CBC levels.</p>
      <p>Peripheral blood samples were taken from the patient for <italic>TPMT</italic> genotyping. After obtaining written informed consent, sequence analysis of all coding exons with their flanking intron regions of <italic>TPMT</italic> gene were performed, and we identified a homozygous variant (c.719A&gt;G; p.Tyr240Cys), <italic>TPMT<sup>*</sup>3C/<sup>*</sup>3C</italic>.</p>
      <p>Simultaneously, 6-TGN and 6-MMPN concentrations were measured by the Waters 2795 Alliance HPLC system and a Quatro Micro API tandem mass spectrometer (Waters, Manchester, UK).<xref ref-type="bibr" rid="B8">8</xref> The thresholds indicating increased likelihood efficacy (6-TGN &gt;235 pmole/8&#xD7;10<sup>8</sup> red blood cells, RBC), increased risk of leukopenia (6-TGN &gt;450 pmole/8&#xD7;10<sup>8</sup> RBC), and increased risk for hapatotoxicity (6-MMPN &gt;5700 pmole/8&#xD7;10<sup>8</sup> RBC) were suggested.<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref> The patient's 6-TGN concentration (7206 pmole/8&#xD7;10<sup>8</sup> RBC) corresponded to a higher risk of leukopenia, although the daily dose had already been reduced from 1.2 mg/kg to 0.8 mg/kg because of neutropenia. The daily dosage was readily decreased to 0.2 mg/kg, and 6-TGN declined to therapeutic levels (437 pmole/8&#xD7;10<sup>8</sup> RBC). Daily AZA dose was reduced further to 0.1 mg/kg as 6-TGN concentration increased again to 745 pmole/8&#xD7;10<sup>8</sup> RBC (<xref ref-type="fig" rid="F1">Fig. 1</xref>). 6-MMPN concentrations were detected at less than the limit of quantitation. The patient's laboratory parameters, including CBC and liver function, were within normal limits during the follow-up period of 24 months.</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>The effect of extremely low or absent TPMT activity can be fatal due to severe myelosuppression. The most significant variants with low TPMT enzyme activity in Western and Asian countries are <italic>TPMT<sup>*</sup>3A</italic> and <italic>TPMT<sup>*</sup>3C</italic>. Compared with Whites, East Asians showed different allele frequencies of <italic>TPMT<sup>*</sup>3A</italic> (Whites vs. East Asians: 3.2-5.7% vs. 0.0%) and <italic>TPMT<sup>*</sup>3C</italic> (0.2-0.8% vs. 0.3-2.3%).<xref ref-type="bibr" rid="B11">11</xref> Although <italic>TPMT<sup>*</sup>3C</italic> is a predominant variant in Asian populations, this is the first case of an IBD patient homozygous for <italic>TPMT<sup>*</sup>3</italic>C in Korea.</p>
      <p>Myelosuppression in IBD patients treated with AZA/6-MP was reported as more common in Koreans (31.0-56.4%)<xref ref-type="bibr" rid="B12">12</xref>-<xref ref-type="bibr" rid="B14">14</xref> than in Western countries (2.0-16.7%).<xref ref-type="bibr" rid="B15">15</xref>-<xref ref-type="bibr" rid="B17">17</xref> The mechanism contributing to a higher incidence of leukopenia in Koreans remains unclear. According to some reports, <italic>TMPT</italic> polymorphisms affected myelotoxicity in only a small portion of patients, in which large numbers of patients with leukopenia also had wild type <italic>TPMT</italic>.<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref> As the <italic>TPMT</italic> genotype could not exclusively elucidate myelosuppression during AZA/6-MP therapy, one possible hypothesis is that genetic variants of genes other than <italic>TPMT</italic>, such as <italic>ITPA</italic> and <italic>MRP4</italic>, involved in thiopurine pharmacokinetics in Asians may also influence inter-individual variability in thiopurines toxicity.<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B21">21</xref></p>
      <p>Because there is genetic variation in thiopurine metabolism, the optimal dose varies. AZA doses are typically reduced by 10-fold and given three times per week instead of daily in the homozygous variant,<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref> while standard doses are given daily at 1.5-2.5 mg/kg in the wild type.<xref ref-type="bibr" rid="B24">24</xref> Currently empiric weight-based dosing adjustment is widely accepted: AZA should be started with low daily doses (0.5-1.5 mg/kg) in order to prevent severe adverse reaction, followed by gradual upward daily dose titration at a maximum of 2.5 mg/kg.<xref ref-type="bibr" rid="B25">25</xref></p>
      <p>In the present case, even after reducing the daily dose of AZA (0.8 mg/kg), the first thiopurine metabolite measurement showed an extremely high 6-TGN level (7206 pmole/8&#xD7;10<sup>8</sup> RBC) and a 6-MMPN concentration less than the quantitation limit. TPMT with deficient activity cannot readily catabolize 6-MP to inactive metabolites, resulting in more 6-MP available for the anabolism of 6-TGN. The secondary metabolite of 6-MP, thioinosine monophosphate (TIMP), is also a substrate for TPMT. Deficient TPMT cannot methylate TIMP to methyl TIMP forming 6-MMPN, which explains why 6-MMPN levels in our patient were less than the quantitation limit. According to the metabolite quantitation results, we reduced the daily maintenance dose (0.1-0.2 mg/kg) by up to 5% of the daily starting dose (1.8 mg/kg). This suggests the importance of metabolite monitoring for individualized-dose adjustment.</p>
      <p>To determine a safe starting dose, evaluation of the <italic>TPMT</italic> genotype or phenotype (TPMT activity) prior to beginning AZA treatment is recommended. Slow metabolizers typically respond to much lower doses of medication. Patients treated with AZA require periodic monitoring of CBC and liver function to prevent AZA-induced toxicities. The monitoring of thiopurine metabolites may be helpful in assessing drug metabolism and optimizing drug dosing, as well as drug-interaction, dosing compliance, and intraindividual variability of TPMT activity during AZA treatment, which cannot be explained exclusively by the <italic>TPMT</italic> genotype.<xref ref-type="bibr" rid="B9">9</xref> The onset of toxicity distinctively develops within one month.<xref ref-type="bibr" rid="B26">26</xref> In cases with a <italic>TPMT</italic> variant, long-term thiopurine therapy is likely to fail because of significant toxicity or an inadequate response during treatment. In this report, our patient had experienced myelosuppression only two weeks after starting AZA therapy. Since dose adjustment based on <italic>TPMT</italic> genotype followed by metabolites monitoring was applied, the patient's disease activity was successfully controlled without relapse of neutropenia.</p>
      <p>In conclusion, this is the first reported case of an IBD patient homozygous for <italic>TPMT<sup>*</sup>3C</italic> in Korea. The patient received successful AZA treatment without recurrent leukopenia after dose optimization based on the presence of the <italic>TPMT</italic> genotype and metabolite monitoring. Our report suggests that AZA dosage should be determined based on the presence of a <italic>TPMT</italic> genotype and with careful metabolite monitoring as this may provide safe and efficient dosing.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>ACKNOWLEDGEMENTS</title>
      <p>We thank the parents of the patient for their collaboration with respect to this report.</p>
      <p>This work was supported by the Samsung Biomedical Research Institute grant, #SBRI GL1-B2-211-1.</p>
    </ack>
    <fn-group>
      <fn fn-type="conflict">
        <p>The authors have no financial conflicts of interest.</p>
      </fn>
    </fn-group>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Appell</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Berg</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Duley</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Evans</surname>
              <given-names>WE</given-names>
            </name>
            <name>
              <surname>Kennedy</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Lennard</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Nomenclature for alleles of the thiopurine methyltransferase gene</article-title>
          <source>Pharmacogenet Genomics</source>
          <year>2013</year>
          <volume>23</volume>
          <fpage>242</fpage>
          <lpage>248</lpage>
          <pub-id pub-id-type="pmid">23407052</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Krynetski</surname>
              <given-names>EY</given-names>
            </name>
            <name>
              <surname>Tai</surname>
              <given-names>HL</given-names>
            </name>
            <name>
              <surname>Yates</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Fessing</surname>
              <given-names>MY</given-names>
            </name>
            <name>
              <surname>Loennechen</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Schuetz</surname>
              <given-names>JD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Genetic polymorphism of thiopurine S-methyl-transferase: clinical importance and molecular mechanisms</article-title>
          <source>Pharmacogenetics</source>
          <year>1996</year>
          <volume>6</volume>
          <fpage>279</fpage>
          <lpage>290</lpage>
          <pub-id pub-id-type="pmid">8873214</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tai</surname>
              <given-names>HL</given-names>
            </name>
            <name>
              <surname>Krynetski</surname>
              <given-names>EY</given-names>
            </name>
            <name>
              <surname>Schuetz</surname>
              <given-names>EG</given-names>
            </name>
            <name>
              <surname>Yanishevski</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Evans</surname>
              <given-names>WE</given-names>
            </name>
          </person-group>
          <article-title>Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>1997</year>
          <volume>94</volume>
          <fpage>6444</fpage>
          <lpage>6449</lpage>
          <pub-id pub-id-type="pmid">9177237</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tai</surname>
              <given-names>HL</given-names>
            </name>
            <name>
              <surname>Krynetski</surname>
              <given-names>EY</given-names>
            </name>
            <name>
              <surname>Yates</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Loennechen</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Fessing</surname>
              <given-names>MY</given-names>
            </name>
            <name>
              <surname>Krynetskaia</surname>
              <given-names>NF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians</article-title>
          <source>Am J Hum Genet</source>
          <year>1996</year>
          <volume>58</volume>
          <fpage>694</fpage>
          <lpage>702</lpage>
          <pub-id pub-id-type="pmid">8644731</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hindorf</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Lindqvist</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hildebrand</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Fagerberg</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Almer</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease</article-title>
          <source>Aliment Pharmacol Ther</source>
          <year>2006</year>
          <volume>24</volume>
          <fpage>331</fpage>
          <lpage>342</lpage>
          <pub-id pub-id-type="pmid">16842460</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dewit</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Starkel</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Roblin</surname>
              <given-names>X</given-names>
            </name>
          </person-group>
          <article-title>Thiopurine metabolism monitoring: implications in inflammatory bowel diseases</article-title>
          <source>Eur J Clin Invest</source>
          <year>2010</year>
          <volume>40</volume>
          <fpage>1037</fpage>
          <lpage>1047</lpage>
          <pub-id pub-id-type="pmid">20629710</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Relling</surname>
              <given-names>MV</given-names>
            </name>
            <name>
              <surname>Gardner</surname>
              <given-names>EE</given-names>
            </name>
            <name>
              <surname>Sandborn</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Schmiegelow</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Pui</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Yee</surname>
              <given-names>SW</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update</article-title>
          <source>Clin Pharmacol Ther</source>
          <year>2013</year>
          <volume>93</volume>
          <fpage>324</fpage>
          <lpage>325</lpage>
          <pub-id pub-id-type="pmid">23422873</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dervieux</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Meyer</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Barham</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Matsutani</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Barry</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Boulieu</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Liquid chromatography-tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine/6-mercaptopurine therapy</article-title>
          <source>Clin Chem</source>
          <year>2005</year>
          <volume>51</volume>
          <fpage>2074</fpage>
          <lpage>2084</lpage>
          <pub-id pub-id-type="pmid">16166171</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dubinsky</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Lamothe</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>HY</given-names>
            </name>
            <name>
              <surname>Targan</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Sinnett</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Th&#xE9;or&#xEA;t</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease</article-title>
          <source>Gastroenterology</source>
          <year>2000</year>
          <volume>118</volume>
          <fpage>705</fpage>
          <lpage>713</lpage>
          <pub-id pub-id-type="pmid">10734022</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cuffari</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Dassopoulos</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Turnbough</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Bayless</surname>
              <given-names>TM</given-names>
            </name>
          </person-group>
          <article-title>Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease</article-title>
          <source>Clin Gastroenterol Hepatol</source>
          <year>2004</year>
          <volume>2</volume>
          <fpage>410</fpage>
          <lpage>417</lpage>
          <pub-id pub-id-type="pmid">15118980</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kumagai</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hiyama</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ishioka</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sato</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yamanishi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>McLeod</surname>
              <given-names>HL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Allelotype frequency of the thiopurine methyltransferase (TPMT) gene in Japanese</article-title>
          <source>Pharmacogenetics</source>
          <year>2001</year>
          <volume>11</volume>
          <fpage>275</fpage>
          <lpage>278</lpage>
          <pub-id pub-id-type="pmid">11337944</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Cheon</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>WH</given-names>
            </name>
          </person-group>
          <article-title>[The frequency and the course of the adverse effects of azathioprine/6-mercaptopurine treatment in patients with inflammatory bowel disease]</article-title>
          <source>Korean J Gastroenterol</source>
          <year>2008</year>
          <volume>51</volume>
          <fpage>291</fpage>
          <lpage>297</lpage>
          <pub-id pub-id-type="pmid">18516013</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Cheon</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Hong</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Eun</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Byeon</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Hong</surname>
              <given-names>SY</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Influences of thiopurine methyltransferase genotype and activity on thiopurine-induced leukopenia in Korean patients with inflammatory bowel disease: a retrospective cohort study</article-title>
          <source>J Clin Gastroenterol</source>
          <year>2010</year>
          <volume>44</volume>
          <fpage>e242</fpage>
          <lpage>e248</lpage>
          <pub-id pub-id-type="pmid">20308917</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Choe</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Yoon</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Ye</surname>
              <given-names>BD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The safety and efficacy of azathioprine and 6-mercaptopurine in the treatment of Korean patients with Crohn's disease</article-title>
          <source>Intest Res</source>
          <year>2009</year>
          <volume>7</volume>
          <fpage>22</fpage>
          <lpage>31</lpage>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hindorf</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Lindqvist</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Peterson</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>S&#xF6;derkvist</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Str&#xF6;m</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hjortswang</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease</article-title>
          <source>Gut</source>
          <year>2006</year>
          <volume>55</volume>
          <fpage>1423</fpage>
          <lpage>1431</lpage>
          <pub-id pub-id-type="pmid">16543290</pub-id>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gisbert</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Ni&#xF1;o</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Rodrigo</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Cara</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Guijarro</surname>
              <given-names>LG</given-names>
            </name>
          </person-group>
          <article-title>Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients</article-title>
          <source>Am J Gastroenterol</source>
          <year>2006</year>
          <volume>101</volume>
          <fpage>2769</fpage>
          <lpage>2776</lpage>
          <pub-id pub-id-type="pmid">17026564</pub-id>
        </element-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zelinkova</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Derijks</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Stokkers</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Vogels</surname>
              <given-names>EW</given-names>
            </name>
            <name>
              <surname>van Kampen</surname>
              <given-names>AH</given-names>
            </name>
            <name>
              <surname>Curvers</surname>
              <given-names>WL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression</article-title>
          <source>Clin Gastroenterol Hepatol</source>
          <year>2006</year>
          <volume>4</volume>
          <fpage>44</fpage>
          <lpage>49</lpage>
          <pub-id pub-id-type="pmid">16431304</pub-id>
        </element-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Colombel</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Ferrari</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Debuysere</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Marteau</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gendre</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Bonaz</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy</article-title>
          <source>Gastroenterology</source>
          <year>2000</year>
          <volume>118</volume>
          <fpage>1025</fpage>
          <lpage>1030</lpage>
          <pub-id pub-id-type="pmid">10833476</pub-id>
        </element-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Takatsu</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Matsui</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Murakami</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ishihara</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hisabe</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nagahama</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease</article-title>
          <source>J Gastroenterol Hepatol</source>
          <year>2009</year>
          <volume>24</volume>
          <fpage>1258</fpage>
          <lpage>1264</lpage>
          <pub-id pub-id-type="pmid">19682195</pub-id>
        </element-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ban</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Andoh</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Imaeda</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kobori</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bamba</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tsujikawa</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease</article-title>
          <source>J Gastroenterol</source>
          <year>2010</year>
          <volume>45</volume>
          <fpage>1014</fpage>
          <lpage>1021</lpage>
          <pub-id pub-id-type="pmid">20393862</pub-id>
        </element-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Uchiyama</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nakamura</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kubota</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yamane</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Fujise</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tajiri</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Thiopurine S-methyltransferase and inosine triphosphate pyrophosphohydrolase genes in Japanese patients with inflammatory bowel disease in whom adverse drug reactions were induced by azathioprine/6-mercaptopurine treatment</article-title>
          <source>J Gastroenterol</source>
          <year>2009</year>
          <volume>44</volume>
          <fpage>197</fpage>
          <lpage>203</lpage>
          <pub-id pub-id-type="pmid">19214663</pub-id>
        </element-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Evans</surname>
              <given-names>WE</given-names>
            </name>
            <name>
              <surname>Horner</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Chu</surname>
              <given-names>YQ</given-names>
            </name>
            <name>
              <surname>Kalwinsky</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>WM</given-names>
            </name>
          </person-group>
          <article-title>Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia</article-title>
          <source>J Pediatr</source>
          <year>1991</year>
          <volume>119</volume>
          <fpage>985</fpage>
          <lpage>989</lpage>
          <pub-id pub-id-type="pmid">1960624</pub-id>
        </element-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaskas</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Louis</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Hindorf</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Schaeffeler</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Deflandre</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Graepler</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine</article-title>
          <source>Gut</source>
          <year>2003</year>
          <volume>52</volume>
          <fpage>140</fpage>
          <lpage>142</lpage>
          <pub-id pub-id-type="pmid">12477776</pub-id>
        </element-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grossman</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Noble</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Mamula</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Baldassano</surname>
              <given-names>RN</given-names>
            </name>
          </person-group>
          <article-title>Increased dosing requirements for 6-mercaptopurine and azathioprine in inflammatory bowel disease patients six years and younger</article-title>
          <source>Inflamm Bowel Dis</source>
          <year>2008</year>
          <volume>14</volume>
          <fpage>750</fpage>
          <lpage>755</lpage>
          <pub-id pub-id-type="pmid">18266236</pub-id>
        </element-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nielsen</surname>
              <given-names>OH</given-names>
            </name>
            <name>
              <surname>Vainer</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Rask-Madsen</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine</article-title>
          <source>Aliment Pharmacol Ther</source>
          <year>2001</year>
          <volume>15</volume>
          <fpage>1699</fpage>
          <lpage>1708</lpage>
          <pub-id pub-id-type="pmid">11683683</pub-id>
        </element-citation>
      </ref>
      <ref id="B26">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boonsrirat</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Angsuthum</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Vannaprasaht</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kongpunvijit</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hirankarn</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Tassaneeyakul</surname>
              <given-names>W</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Azathioprine-induced fatal myelosuppression in systemic lupus erythematosus patient carrying TPMT*3C polymorphism</article-title>
          <source>Lupus</source>
          <year>2008</year>
          <volume>17</volume>
          <fpage>132</fpage>
          <lpage>134</lpage>
          <pub-id pub-id-type="pmid">18250137</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" orientation="portrait" position="float">
      <label>Fig. 1</label>
      <caption>
        <p>Absolute neutrophil count (ANC) and erythrocyte 6-thioguanine nucleotides (6-TGN) concentrations according to dosages of azathioprine. Leukopenia was developed 2 weeks after starting azathioprine (AZA). AZA was reduced and discontinued. After leukopenia was recovered, AZA treatment was restarted. The patient continued to receive AZA treatment with optimized daily dose adjustments (0.1-0.2 mg/kg) and ANC was maintained within normal limits by monitoring thiopurine metabolites such as 6-TGN. RBC, red blood cells; TPMT, thiopurine S-methyltransferase.</p>
      </caption>
      <graphic xlink:href="ymj-54-1545-g001"/>
    </fig>
  </floats-group>
</article>
</pmc-articleset>
